Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced its third-quarter 2022 financial results will be released on November 8, 2022, before U.S. markets open. Management plans to host a conference call at 8:00 a.m. ET to discuss the results and recent corporate developments. The company focuses on improving lives in genetically defined rare diseases and has ongoing clinical programs for losmapimod for FSHD and FTX-6058 for sickle cell disease. Interested parties can access the call through the Investor Relations section of the company's website.

Positive

• Ongoing clinical development of losmapimod and FTX-6058.
• Focus on unmet medical needs in genetically defined rare diseases.

Negative

• None.

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S. Dial-in Number: 833-634-2546
International Dial-in Number: 412-902-4190
All participants should ask to be connected to the Fulcrum Therapeutics conference call.

Replay U.S. Dial-in Number: 877-344-7529
Replay Canada Dial-In Number: 855-669-9658
Replay International Dial-in Number: 412-317-0088
Replay Access Code: 2495296

An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.

Contacts:

Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media
Dee Smith
Executive Director, Corporate Communications
dsmith@fulcrumtx.com
202-746-1324

FAQ

When will Fulcrum Therapeutics release its third-quarter 2022 financial results?

Fulcrum Therapeutics will release its third-quarter 2022 financial results on November 8, 2022, before U.S. market open.

What time is the conference call for Fulcrum's financial results?

The conference call for Fulcrum's financial results will take place at 8:00 a.m. ET on November 8, 2022.

What are the key programs Fulcrum Therapeutics is working on?

Fulcrum Therapeutics is focusing on losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.